Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 2/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 8/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | METAP2 | P50579 | 1/20 | 0.36 |
| ▸ | METAP1 | P53582 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2646677 | 1.00 | KCNH2 (0.42) | KCNH2SLC6A3LMNAP2RX7EPHX2 | |
| SCHEMBL2662658 | 1.00 | KCNH2 (0.42) | KCNH2SLC6A3LMNAP2RX7EPHX2 | |
| SCHEMBL2645704 | 1.00 | KCNH2 (0.42) | KCNH2SLC6A3LMNAP2RX7EPHX2 | |
| SCHEMBL2662801 | 0.94 | KCNH2 (0.43) | KCNH2SLC6A3LMNAEPHX2METAP2 | |
| SCHEMBL2644753 | 0.94 | KCNH2 (0.43) | KCNH2SLC6A3LMNAEPHX2METAP2 | |
| SCHEMBL2645714 | 0.89 | KCNH2 (0.43) | KCNH2SLC6A3LMNAMETAP2METAP1 | |
| SCHEMBL2662486 | 0.89 | KCNH2 (0.43) | KCNH2SLC6A3LMNAMETAP2METAP1 | |
| SCHEMBL2646330 | 0.88 | KCNH2 (0.44) | KCNH2SLC6A3LMNACYP1A2CYP3A4 | |
| SCHEMBL2646821 | 0.87 | KCNH2 (0.42) | KCNH2SLC6A3LMNAMETAP2METAP1 | |
| SCHEMBL2645894 | 0.86 | KCNH2 (0.46) | KCNH2SLC6A3LMNAEPHX2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7534593-B2 | Crystals of glucokinase and methods of growing them | HOFFMANN-LA ROCHE INC. (US) | 2009-05-19 | — | — | US | claimed |
| US-7534593-B2 | Crystals of glucokinase and methods of growing them | HOFFMANN-LA ROCHE INC. (US) | 2009-05-19 | — | — | US | disclosed |
| US-20060141599-A1 | Crystals of Glucokinase and methods of growing them | CORBETT WENDY L | 2006-06-29 | — | — | US | disclosed |
| US-6911545-B2 | Crystals of glucokinase and methods of growing them | HOFFMAN-LA ROCHE INC. (US) | 2005-06-28 | — | — | US | disclosed |
| US-20030219887-A1 | Crystals of glucokinase and methods of growing them | HOFFMANN-LA ROCHE INC. | 2003-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030219887-A1 | Crystals of glucokinase and methods of growing them | GCK, GCKR, GALK1 | KCNH2 1294/4885SLC6A3 2940/4885LMNA 3719/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.